Pathway Bioventures

Pathway Bioventures is a venture capital firm dedicated to transforming lives through advanced therapeutics. The firm primarily invests in seed-stage precision therapeutics companies that are addressing significant unmet medical needs. Their investment focus spans breakthrough technologies in genetic medicine, targeted therapies, medical devices, and diagnostics, aiming to back outstanding entrepreneurs who are innovating in the life sciences sector.

Daniel Jacobs founded Pathway Bioventures in 2018 with the mission to accelerate the growth of groundbreaking early-stage life sciences companies. The firm's inception was driven by a recognition of the profound potential of novel therapeutic approaches and a commitment to supporting visionary entrepreneurs in biotechnology. Pathway Bioventures provides both capital and strategic guidance, particularly focusing on assisting companies through the critical seed to Series A transition.

The firm has built a notable portfolio of revolutionary companies. Key investments include Modifi Bio, which was acquired by Merck, as well as Biograph55 and miRecule. More recently, Pathway Bioventures participated in the Series A financing of Cytospire Therapeutics, a UK-based biotech developing next-generation oncology immunotherapies. Other portfolio companies mentioned in various sources include Nionyx, Axonis Therapeutics, AIRNA, CytoVale, Simergent, Ochre Bio, Dimension Inx, and Scioto Biosciences.

Pathway Bioventures boasts a team with deep scientific and entrepreneurial expertise. Daniel Jacobs, the Founder and Managing Partner, is a cancer researcher with expertise in cancer epidemiology, genomics, and RNA therapeutics. Matt Martin, a Partner, brings 15 years of management experience from universities, startups, and early-stage investment groups, and is the founding CEO of Saros Therapeutics. Jacob Segil, a Venture Partner, is a research professor and managing director at the Center for Translational Research, with experience founding medical device companies. Strategic Advisor Marta New is an experienced drug developer and biotech investor, while Investment Consultant David Hardwicke contributes his background in technology commercialization and drug development.